Compare PCT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | MESO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Australia |
| Employees | 174 | 81 |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | N/A |
| Metric | PCT | MESO |
|---|---|---|
| Price | $11.36 | $15.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 138.6K |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $380.44 | $629.74 |
| Revenue Next Year | $203.33 | $30.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $9.88 |
| 52 Week High | $17.37 | $21.50 |
| Indicator | PCT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 51.33 |
| Support Level | $7.87 | $14.19 |
| Resistance Level | $15.13 | $16.31 |
| Average True Range (ATR) | 0.85 | 0.36 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 66.58 | 52.35 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.